Background: Calcium plays an essential role in nearly all cellular processes. As such, cellular and systemic calcium concentrations are tightly regulated. During sepsis, derangements in such tight regulation frequently occur, and treating hypocalcemia with parenteral calcium administration remains the current practice guideline. Objective: We investigated whether calcium administration worsens mortality and organ dysfunction using an experimental murine model of sepsis and explored the mechanistic role of the family of calcium/calmodulin-dependent protein kinases in mediating these physiological effects. To highlight the biological relevance of these observations, we conducted a translational study of the association between calcium administration, organ dysfunction, and mortality among a cohort of critically ill septic ICU patients. Design: Prospective, randomized controlled experimental murine study and observational clinical cohort analysis. Setting: University research laboratory and eight ICUs at a tertiary care center. Patients: A cohort of 870 septic ICU patients. Subjects: C57Bl/6 and CaMKK −/− mice. Interventions: Mice underwent cecal ligation and puncture polymicrobial sepsis and were administered with calcium chloride (0.25 or 0.25 mg/kg) or normal saline. Measurements and Main Results: Administering calcium chloride to septic C57Bl/6 mice heightened systemic inflammation and vascular leak, exacerbated hepatic and renal dysfunction, and increased mortality. These events were significantly attenuated in CaMKK −/− mice. In a risk-adjusted analysis of septic patients, calcium administration was associated with an increased risk of death, odds ratio 1.92 (95% CI, 1.00−3.68; p = 0.049), a significant increase in the risk of renal dysfunction, odds ratio 4.74 (95% CI, 2.48−9.08; p < 0.001), and a significant reduction in ventilator-free days, mean decrease 3.29 days (0.50−6.08 days; p = 0.02). Conclusions: Derangements in calcium homeostasis occur during sepsis that is sensitive to calcium administration. This altered calcium signaling, transduced by the calmodulin-dependent protein kinase kinase cascade, mediates heightened inflammation and vascular leak that culminates in elevated organ dysfunction and mortality. In the clinical management of septic patients, calcium supplementation provides no benefit and may impose harm. (Crit Care Med 2013; 41:e352-e360) 
C alcium plays an essential role in nearly all biological processes. As such, ionized calcium concentration [Ca 2+ ] i is tightly regulated at both the cellular and systemic levels. However, during critical illness, derangements in calcium homeostasis occur with considerable frequency. Indeed, hypocalcemia is prevalent in up to 88% of critically ill patients (1) (2) (3) (4) . Prior studies suggest that the development of hypocalcemia is an independent risk factor for increased mortality (1) (2) (3) . However, a causal relationship between hypocalcemia and either organ dysfunction or mortality has not been elucidated (5) .
These observations led to the current practice guideline of treating low [Ca 2+ ] i with the parenteral administration of calcium (2, (6) (7) (8) (9) (10) . However, evidence has emerged to challenge this common practice. A recent systematic review concluded that there is no evidence to support treating hypocalcemia of critical illness (11) . Further, animal models of sepsis and trauma have demonstrated that calcium supplementation actually worsens mortality and organ dysfunction (12) (13) (14) (15) (16) , whereas calcium antagonism may improve cellular function (17) (18) (19) (20) .
Currently, it is hypothesized that dysregulated intracellular calcium handling underlies the potential detriment in parenteral calcium supplementation to address hypocalcemia of critical illness (15, 21) . Though systemic [Ca 2+ ] i is low, intracellular [Ca 2+ ] i is high in the setting of sepsis and trauma. These alterations in intracellular [Ca 2+ ] i are thought to contribute to a heightened inflammatory response, cellular death, and subsequent organ dysfunction (16, (21) (22) (23) (24) (25) (26) (27) (28) (29) .
Though derangements in calcium handling have been implicated in critical illness, the specific mechanisms underlying this process remain unknown. The calcium/calmodulin-dependent protein kinases (CaMKs) are a family of multifunctional kinases, sensitive to changes in intracellular [Ca 2+ ] and, thus, may act as receivers of these abnormal calcium signals. The CaMKs coordinate a variety of cellular functions, including gene expression, cell cycle progression, and apoptosis, and recent data suggest that specific CaMK members play a functional role in innate immunity (30) (31) (32) (33) (34) (35) .
In this study we propose that 1) the administration of parenteral calcium worsens mortality and organ dysfunction in a murine model of intra-abdominal sepsis, 2) the CaMK cascade plays a mechanistic role in mediating these physiological and clinical effects, and 3) a T1 translational clinical study will demonstrate an association between calcium administration, organ dysfunction, and mortality among a cohort of critically ill septic ICU patients, thus highlighting the relevance of our observations to human biology.
MATERIALS AND METHODS

Reagents
Evans Blue dye (Sigma, St. Louis, MO) was reconstituted in phosphate-buffered saline (PBS). Imipenem (Merck, Whitehouse Station, NJ) was reconstituted in normal saline (NS). Calcium chloride (CaCl 2 , 10% [w/v]) was purchased from American Regent (Shirley, NY). The broad CaMK inhibitor, KN93 (Calbiochem), and its less functional analog KN92, were dissolved in sterile PBS.
Animal Experimentation
We performed all animal experiments in accordance with the National Institutes of Health guidelines under protocols approved by the Institutional Animal Care and Use Committee of the University of Pittsburgh. We randomly assigned 6-to 8-week-old male mice of C57Bl/6J and B6.129X1-Camkk1tm1Tch/J (CaMKK −/− [CaMKK-CaMK kinase]) strains to a specific experiment. The CaMKK −/− strain is derived from a C57Bl/6J background; these mice are viable and fertile and do not display any gross physical abnormalities.
We performed cecal ligation and puncture (CLP) as previously described, using a single 21-G puncture (31, 32) .
Imipenem/Cilastin (0.75 mg/kg, SQ) was administered 12 hours postoperatively. Treatment groups consisted of CaCl 2 (0.25 or 2.5 mg/kg) or 0.9% NS isovolemic control administered 12 hours after CLP by IP injection. For animals assigned to biochemical CaMK manipulation, KN93 or KN92 (6 mg/kg, IP) was administered 12 hours and 1 hour prior to CLP.
For all studies, one investigator performed the surgical experimentation and collected the samples. A separate individual administered with NS and CaCl 2 without prior knowledge of the surgical treatment. The data were then analyzed by an investigator blinded to the specific treatment.
Evans Blue Permeability
Mice were anesthetized, and a 1% (w/v) solution of Evans Blue dye was administered by lateral tail vein injection (36, 37) . After 30 minutes, the intravascular compartment was flushed by right ventricular injection of 1 mL of NS. The lungs, liver, and kidneys were then collected and stored overnight in 1 mL of formamide at 55°C. The Evans Blue content of the extracts was measured by spectrometry (OD 620 -O D500 ).
Organ Physiology
Serum concentrations of alanine aminotransferase (ALT) and blood urea nitrogen (BUN) were quantitatively determined using an HESKA DRI-CHEM Analyzer.
Enzyme-Linked Immunosorbent Assay
Concentrations of interleukin (IL)-10, tumor necrosis factor (TNF)-α, and IL-6 were quantified by an enzyme immunoassay kit (R&D Systems, Minneapolis, MN).
Myeloperoxidase Activity
Tissue myeloperoxidase determination assay was modified from previously published sources (38, 39) . Snap-frozen tissues were weighed and homogenized in myeloperoxidase buffer (6.8 g KH 2 PO 4 and 8.7 g K 2 HPO 4 in 1 L H 2 O) containing 0.5% hexadecyltrimethylammonium bromide at a ratio of 50 mg tissue:1 mL myeloperoxidase buffer. The homogenate was centrifuged (20,000 × g) for 4 minutes at 4°C. Supernatant of 7 μL of was placed into a 96-well plate with 200 μL of O-dianisidine hydrochloride solution. Each sample was measured in triplicate, and the average used to calculate the myeloperoxidase activity by dividing the ∆absorbance 450 nm (0-60 seconds)/time (min)/mL by the extinction coefficient, 1.13 × 10 -2 .
Statistical Analysis
Statistical analyses were performed using Stata 12 SE software (College Station, TX). Values are expressed as mean ± sem. Groups are compared by nonparametric Wilcoxon signed rank test. A p value of less than 0.05 was considered statistically significant.
CLINICAL STUDY
Study Design
We conducted a retrospective cohort study to determine the association between calcium administration and mortality or organ dysfunction among septic ICU patients. We used the University of Pittsburgh Medical Center (UPMC) Acute Physiology and Chronic Health Evaluation (APACHE) III dataset, an ongoing database that randomly calculates APACHE III scores for one third of patients (40, 41) . De-identified data were linked to electronic demographic, clinical, and pharmacological data from the High Density Intensive Care (HiDenIC) database, which retrospectively collects information on patients admitted to eight ICUs at UPMC Presbyterian and Montefiore hospitals (40, 41) . This study was approved by the Institutional Review Board at the University of Pittsburgh.
Patients
Demographic and physiological variables were available for 1,276 patients admitted between June 30, 1999 and July 31, 2004 with a primary diagnosis of sepsis. Of these, 870 (82.6%) possessed calculated APACHE III scores and formed the cohort for analysis. We focused our analysis on patients requiring more than 24 hours of ICU care.
Variables and Risk Adjustment
Our primary exposure of interest was parenteral calcium administration: total ampules of calcium chloride or calcium gluconate administered parenterally. The primary outcome was hospital mortality during the index admission. We examined cumulative calcium administration both as a continuous variable (0, 1, 2, and ≥ 3 doses) and as a binary outcome (calcium vs none). Secondary outcomes included acute renal dysfunction (creatinine > 2.0 mg/dL) and the highest BUN concentration. Pulmonary dysfunction was quantified using ventilator-free days (VFDs) (42) .
We addressed potential confounding by controlling for the severity of illness, quartiles of lowest [Ca 2+ ] i , and additional variables related to the outcome. Hypocalcemia was defined as a serum [Ca 2+ ] i < 1.15 mEq/L (2). The severity of illness was determined according to the APACHE III score (range, 0-299) (43) . Other risk-adjustment variables included age, sex, race, the season and year of admission, and the type of ICU.
Statistical Analyses
We performed a random effects multivariate logistic regression to assess the association between the parenteral administration of calcium and the risk of mortality, calculating crude and adjusted odds ratios (aORs) with 95% CIs, accounting for the correlation within ICUs and covariates specified a priori as potential confounders: age, sex, race, season and year, ICU location, APACHE III, and quartiles of lowest [Ca 2+ ] i . We explored whether the association between calcium supplementation and mortality varied with the degree of hypocalcemia by including an interaction term between calcium administration and the hypocalcemia covariate. A similar analysis was performed to assess the association between calcium administration and the development of renal dysfunction and pulmonary dysfunction. A p value of less than 0.05 was considered significant.
RESULTS
Calcium Supplementation During Sepsis Worsens Organ Function and Mortality in Septic ICU Patients
A total of 526 of 870 (60.4%) septic ICU patients had at least one measurement of total calcium or [Ca 2+ ] i ( Table 1) . The mean nadir [Ca 2+ ] i was 1.09 ± 0.14 mEq/L, and 377 (71.7%) were hypocalcemic. Of these 526 patients, 93 (17.7%) received parenteral calcium and a median of 1 [interquartile range, 0-2] ampule of calcium. Those receiving calcium had higher APACHE III scores 80.0 versus 66.4, p < 0.001. Those patients for whom [Ca 2+ ] i was not measured were less ill with a mean APACHE III score of 58.9, and only seven patients (2.0%) received calcium.
In multivariate analysis, the magnitude of hypocalcemia was not associated with an increased risk of death: [Ca 2+ ] i 1.00-1.15 mEq/L, aOR 1.01 (95% CI, 0.56-1.79; p = 0.57); [Ca 2+ ] i 0.85-0.99 mEq/L, aOR 1.27 (95% CI, 0.56-2.86; p = 0.97); [Ca 2+ ] i < 0.85 mEq/L, aOR 1.02 (95% CI, 0.27-3.92; p = 0.97). However, the administration of any calcium was associated with an increased risk of death, aOR 1.92 (95% CI, 1.00-3.68; p = 0.049) ( Fig. 1) . With calcium as a continuous variable, increasing doses of calcium were associated with increased mortality, aOR 1.53 (95% CI, 1.10-2.13; p = 0.01). The association was similar for calcium chloride and calcium gluconate. An adjusted analysis incorporating those patients without [Ca 2+ ] i measurements yielded similar results, aOR 2.11 (95% CI, 1.18-3.78; p = 0.01). There was no significant association between the magnitude of hypocalcemia and renal dysfunction (data not shown). Yet, parenteral calcium was associated with a significant increase in BUN, adjusted mean increase 15.5 mg/dL (95% CI, 6.18-24.9; p < 0.001), and risk of renal dysfunction, aOR 4.74 (95% CI, 2.48-9.08; p < 0.001). Increasing doses of calcium were associated with an increased risk of renal dysfunction (aOR, 2.08; 95% CI, 1.45-2.98; p < 0.001) and BUN (8.44 mg/dL; 95% CI, 3.48-13.4; p = 0.001). There was no significant association between the magnitude of hypocalcemia and VFD (data not shown). However, parenteral calcium was associated with reduced VFD, adjusted mean decrease 3.29 days (0.50-6.08 days, p = 0.02).
Calcium Supplementation During Sepsis Induces Organ Failure and Increases Mortality
We explored whether physiological doses of CaCl 2 altered mortality in a murine model of sepsis. We observed an apparent dose-response relationship between CaCl 2 and increased death (Fig. 2) . By comparison to NS, CaCl 2 (0.25 mg/kg) increased mortality: 8.3% versus 50% (p = 0.01). At a CaCl 2 dose of 2.5 mg/kg, mortality was further increased to 66.7% (p = 0.001). This increased mortality appeared to be mediated by an exacerbation in organ injury/dysfunction. As shown in Figure 3 , CaCl 2 (2.5 mg/kg) worsened both liver injury and renal dysfunction: serum ALT (30 ± 2.4 vs 155 ± 53.9 mg/ dL; p = 0.009) and BUN (19 ± 4.6 vs 90.7 ± 31.0 mg/dL; p = 0.049).
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CaMKK Mediates Calcium Signaling and the Increased Risk of Organ Failure and Mortality
Our laboratory has previously shown that members of the CaMK mediate the inflammatory response during sepsis (31, 32) . As shown in Figure 2 , the increased mortality with CaCl 2 (2.5 mg/ kg) was attenuated in CaMKK −/− mice: 66.7% versus 33.3%, p = 0.03. Similarly, organ injury/dysfunction induced by CaCl 2 was reduced in CaMKK −/− mice: ALT (51.8 ± 6.5 vs 155 ± 53.9; p = 0.06) and BUN (23.5 ± 1.0 vs 90.7 ± 31.0; p = 0.04) ( Fig. 3) .
Calcium Administration During Sepsis Heightens and Prolongs Systemic Inflammation via CaMKK Signaling
We observed that lipopolysaccharide elevates Mφ cytosolic [Ca 2+ ] (data not shown). We hypothesized that calcium administration heightens inflammation. As shown in Figure 4 , CaCl 2 (2.5 mg/kg) elevated and prolonged heightened systemic concentrations of TNF-α, IL-10, and IL-6 in wild-type (WT) mice, which was not observed in CaMKK −/− mice. Pharmacological blockade of CaMK using KN93, by comparison to its inactive analog KN92, similarly attenuated the increase in TNF-α and IL-10 induced with CaCl 2 (Fig. 5) . Twelve hours following CaCl 2 , the spleen exhibited a marked increase in myeloperoxidase activity that was attenuated in CaMKK −/− mice (103.8 ± 13.4 vs 66.1 ± 3.3; p = 0.05) (data not shown). Thus, our data suggest that calcium supplementation heightens the inflammatory response during sepsis.
Calcium Supplementation During Sepsis Increases Vascular Permeability via CaMKK Signaling
In light of the systemic alterations in inflammation and in organ function, we hypothesized that a common theme of increased vascular leak might underlie our observations. Indeed, CaCl 2 significantly worsened vascular leak ( Fig. 6) . However, this was attenuated in CaMKK −/− by comparison to WT mice: liver (0.09 vs 0.25; p = 0.11), kidney (0.16 vs 0.25; p = 0.08), and lung (0.08 vs 0.33; p = 0.003). Using hematoxylin and eosin staining, we did not observe any histological differences in cellular or organ architecture at 12 hours after CaCl 2 or NS (data not shown).
DISCUSSION
During critical illness, perturbations in systemic electrolyte concentrations are commonly observed (2, 5, 44) . These deviations have classically been considered harmful and thus necessitate monitoring and medical treatment (44) (45) (46) . Studies do support a benefit in maintaining certain threshold concentrations of potassium and magnesium (47) (48) (49) . However, evidence for a similar approach to address hypocalcemia is sparse (5, 11) . In a murine model of severe sepsis, we observed an apparent dose-response relationship between a single pharmacological dose of calcium and an increased risk of organ dysfunction and death. These untoward ramifications appear to be mediated by a CaMK-dependent exacerbation in vascular leak and shock. The clinical relevance of these biological observations is highlighted by a risk-adjusted clinical analysis demonstrating an association between parenteral calcium administration and increased pulmonary and renal dysfunction and death. The high prevalence of hypocalcemia of critical illness and its association with elevated mortality was first described decades ago and subsequently reported in several independent analyses of both medical and surgical populations (1) (2) (3) 7) . Cognizant that calcium homeostasis is essential for normal cell function and organ physiology, the medical community has viewed this relationship as causal. However, contemporary critics propose that hypocalcemia is merely a surrogate marker of severity of illness, a confounding characteristic not incorporated into these prior associative studies (5) . In our analysis, we did not identify a significant association between the magnitude of hypocalcemia and renal dysfunction, VFD, or death. Other recent studies either confirm our observations or identify elevated mortality only in the setting of severe hypocalcemia (i.e., [Ca 2+ ] < 0.80 mEq/L) (5, 50) . Thus, the existing observational evidence strongly supports that mild to moderate hypocalcemia is not causally associated with worse outcome.
Numerous studies have shown that despite hypocalcemia, intracellular [Ca 2+ ] is elevated in a variety of models of severe illness (51) (52) (53) . High intracellular [Ca 2+ ] is toxic, and all cells require an effective homeostatic system to maintain intracellular [Ca 2+ ] at 100 nM, about 20,000 times lower than the extracellular mileu (54, 55) . These mechanisms are altered during sepsis C57Bl/6 and CaMKK −/− mice were subjected to cecal ligation and puncture, followed by normal saline (NS, 3 mL/100 g) and imipenem/ cilastatin (0.5 mg/kg) administration. After 12 hr, mice were administered with CaCl 2 (0.25 or 2.5 mg/kg) or equivolume NS by IP injection. Survival was assessed every 6 hr for 7 d. *Compared with C57Bl/6 receiving NS. †Compared with C57Bl/6 receiving 2.5 mg/kg CaCl 2 (n = 12 animals per group).
Figure 3.
Calcium administration during sepsis induces liver injury and renal dysfunction via calcium/calmodulin-dependent protein kinase kinase (CaMKK) signaling. C57Bl/6 and CaMKK −/− mice were subjected to cecal ligation and puncture, followed by normal saline (NS, 3 mL/100 g) and imipenem/cilastatin (0.5 mg/kg) administration. After 12 hr, mice were administered with CaCl 2 (2.5 mg/kg) or equivolume NS by IP injection. After 24 hr, mice were euthanized, blood was isolated by cardiac puncture, and the serum was analyzed for alanine aminotransferase (ALT) concentrations and blood urea nitrogen (BUN) (n = 12 animals per group).
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Collectively, these data call for a reassessment of our current perspective of hypocalcemia of critical illness (6) (7) (8) (9) (10) . A recent systematic review concluded that there are no data to support parenteral calcium supplementation among critically . Calcium administration during sepsis heightens and prolongs systemic inflammation via calcium/calmodulin-dependent protein kinase kinase (CaMKK) signaling. C57Bl/6 and CaMKK −/− mice were subjected to cecal ligation and puncture, followed by normal saline (NS, 3 mL/100 g) and imipenem/cilastatin (0.5 mg/kg) administration. After 12 hr, mice were administered with CaCl 2 (2.5 mg/kg) or equivolume NS by IP injection. At the timepoints indicated, blood was isolated by cardiac puncture, and the serum was analyzed for cytokine concentrations. *Compared with C57Bl/6 receiving 2.5 mg/kg CaCl 2 (n = 6-8 animals per group). Figure 5 . Calcium administration during sepsis heightens systemic inflammation via calcium/calmodulin-dependent protein kinase (CaMK) signaling. C57Bl/6 were IP administered with the broad CaMK inhibiter KN93 (6 mg/kg) or its inactive analog, KN92 (6 mg/kg), 12 and 1 hr prior to experimentation. Mice were then subjected to cecal ligation and puncture, followed by normal saline (NS, 3 mL/100 g) and imipenem/ cilastatin (0.5 mg/kg) administration. After 12 hr, mice were administered with CaCl 2 (2.5 mg/kg) or equivolume NS by lateral tail vein injection. After 16 hr, blood was isolated by cardiac puncture, and the serum was analyzed for cytokine concentrations (n = 6-8 animals per group). ill patients (11) . We observed that a single pharmacological dose of calcium heightened inflammation and vascular leak that correlated with worse organ dysfunction and mortality in mice. Other animal studies, albeit administering much higher doses of calcium, have observed similar increases in death with calcium supplementation, though causal mechanisms were not explored (17, 19) . Intracellular [Ca 2+ ] is elevated in immune cells of septic patients (51) . In vitro studies have shown that elevating intracellular [Ca 2+ ] heightens lipopolysaccharideinduced monocyte/macrophage cytokine production (56) . Thus, we hypothesized that calcium administration heightens inflammation, which culminates in increased vascular leak and shock, and greater organ dysfunction and mortality. This perspective is supported by our in vivo studies, wherein CaMKK −/− mice exhibited resistance to calciuminduced elevations in systemic inflammation and an attenuation in vascular leak that reduced organ dysfunction/injury and mortality. Others and we have described the dependency of septic inflammation on CaMK signaling. In an in vivo model of intra-abdominal sepsis, a CaMKK-CaMKI signaling pathway regulated systemic HMGB1 and IL-10 release that was causally related to the development of renal dysfunction (31) . More recently, the function of this CaMKK-CaMKI cascade has been extended to include alveolar cytokine concentrations during lipopolysaccharide-induced acute lung injury. CaMKIV serves as a component of a signaling pathway that regulates bcl-2-dependent dendritic cell survival and lipopolysaccharide-induced macrophage HMGB1 production (32, 57, 58) . Both effector kinases are regulated by the upstream CaMKK studied herein (30) . Thus, we hypothesize that the physiological perturbations induced by calcium supplementation are consequential to CaMKK-dependent inflammation. Of note, though broad biochemical CaMK inhibition attenuated IL-6, CaMKK inhibition did not, suggesting that an alternate CaMK, such as CaMKII, I or IV, regulates calcium-induced elevations in IL-6 during sepsis. We recognize that alternate mechanisms, including endothelial and parenchymal CaMKK signaling, may underlie the alterations in vascular leak and organ physiology/injury.
We recognize that limitations exist that may explain some of our observations. A significant proportion of patients did not have [Ca 2+ ] measurements. However, the associations between calcium administration and each outcome for the entire cohort were similar to those of the final analyzed cohort possessing [Ca 2+ ] measurements. Patients receiving calcium were more ill and exhibited lower nadirs of [Ca 2+ ]. However, after including a host of validated covariates, including APACHE III scores, the associations persisted. Furthermore, our murine studies, which were performed in a randomized, blinded, and controlled fashion, yielded similar results. We acknowledge that the magnitude of the associations in the clinical cohort was less than that observed in the murine model. Many additional interventions are pursued to achieve survival in the context of human disease: volume resuscitation, vasopressors, and cardiopulmonary resuscitation. Furthermore, the clinical study also represents a heterogeneous spectrum of disease Figure 6 . Calcium administration during sepsis increases vascular permeability via calcium/calmodulin-dependent protein kinase kinase (CaMKK) signaling. C57Bl/6 and CaMKK −/− mice were subjected to cecal ligation and puncture, followed by normal saline (NS, 3 mL/100 g) and imipenem/cilastatin (0.5 mg/kg) administration. After 12 hr, mice were administered with CaCl 2 (2.5 mg/kg) or equivolume NS by IP injection. After 12 hr, each organ was harvested and vascular permeability assessed by Evans Blue dye as detailed in Materials and Methods (n = 6 animals per group). Top panel represents data from liver, middle panel represents data from kidney, and bottom panel represents data from lung.
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CONCLUSIONS
In conclusion, the combined data of our murine and translational human studies suggest that calcium supplementation provides no benefit in the management of severe sepsis and may impose harm. Recognizing that hypocalcemia and critical illness are both continuums, we propose that further studies are needed to determine if a threshold [Ca 2+ ] concentration exists, below which, such therapy is warranted. The collective evidence, to which these new data are added, highlights that a derangement in homeostatic calcium regulation evolves during sepsis that is sensitive to manipulation by calcium administration. This altered calcium signaling, transduced by the CaMKK cascade, mediates a heightened state of inflammation and vascular leak that culminates in elevated organ dysfunction and mortality. Further investigations to determine the exact location and mechanisms of CaMKK signaling that mediate the physiological perturbations observed will contribute to the understanding, and hopefully management, of sepsis and critical illness.
